<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part3">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>3</PartID>
        <PartNumber>Part II</PartNumber>
        <PartSequenceNumber>3</PartSequenceNumber>
        <PartTitle>Chemotherapy</PartTitle>
        <PartChapterCount>6</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap11" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>11</ChapterID>
          <ChapterNumber>Chapter 11</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_11</ChapterDOI>
          <ChapterSequenceNumber>11</ChapterSequenceNumber>
          <ChapterTitle Language="En">Mitoxantrone</ChapterTitle>
          <ChapterFirstPage>125</ChapterFirstPage>
          <ChapterLastPage>131</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>3</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_11" CorrespondingAffiliationID="Aff1_11">
              <AuthorName DisplayOrder="Western">
                <GivenName>Patricia</GivenName>
                <FamilyName>Halterman</FamilyName>
              </AuthorName>
              <Contact>
                <Email>phalterman@nvcancer.org</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Nicholas</GivenName>
                <GivenName>J.</GivenName>
                <FamilyName>Vogelzang</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Alireza</GivenName>
                <FamilyName>Farabishahadel</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Oscar</GivenName>
                <GivenName>B.</GivenName>
                <FamilyName>Goodman</FamilyName>
                <Suffix>Jr.</Suffix>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_11">
              <OrgDivision>Clinical Pharmacy</OrgDivision>
              <OrgName>Nevada Cancer Institute</OrgName>
              <OrgAddress>
                <City>Las Vegas</City>
                <State>NV</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_11" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Mitoxantrone (dihydroxyanthracenedione, DHAD) is an anthracenedione derivative developed in the 1970s in an effort to find a less cardiotoxic doxorubicin derivative. Although the exact mechanism of action remains unclear, mitoxantrone intercalates between base pairs of the DNA double helix, resulting in cross links, strand breaks, and inhibition of nucleic acid synthesis. Early studies with mitoxantrone demonstrated a low potential for drug–drug interactions, other than a significantly increased risk of infection when administered concomitantly with live vaccines. Currently, there are five black box warnings described in the US package insert. Initially approved in 1987 for treatment of acute non-lymphocytic leukemia (ANLL – now AML) in adults, mitoxantrone was approved in 1996 for use in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced castration-resistant prostate cancer (CRPC). For this indication, the recommended dosage is 12–14 mg/m<Superscript>2</Superscript> every 3 weeks, as a 30-min intravenous infusion. In multiple large randomized studies, mitoxantrone plus prednisone was shown to reduce pain and increase quality of life for patients with CRPC, though it does not extend survival. Subsequent to the approval of docetaxel as a treatment for CRPC, mitoxantrone has primarily been used as a second-line therapy.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Mitoxantrone</Keyword>
            <Keyword>DHAD</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>CRPC</Keyword>
            <Keyword>Salvage therapy</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Mitoxantrone is an anthracenedione derivative developed in the 1970s, a discovery of the synthetic chemistry program at the Medicinal Research Division of the American Cyanamid Company [<CitationRef CitationID="CR1_11">1</CitationRef>]. Development began with a molecule predicted to favor intercalation with double-stranded DNA. From this original class of compounds with immunomodulatory effects and significant activity against murine tumors, mitoxantrone was selected for further development based on its potency and excellent tumor activity. Mitoxantrone is cytotoxic to both proliferating and nonproliferating cells.</Para>
            <Para TextBreak="No">Since its initial approval in 1987 for treatment of acute nonlymphocytic leukemia (ANLL – now AML) in adults, mitoxantrone continues to demonstrate efficacy in treatment of recurrent AML. When used in combination with cytarabine, response rate has been reported at 50–60% in first relapse [<CitationRef CitationID="CR2_11">2</CitationRef>] and at 55% when utilizing the MEC regimen (mitoxantrone, etoposide, and cytarabine) [<CitationRef CitationID="CR3_11">3</CitationRef>]. Mitoxantrone was approved in 1996 for use in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced castration-resistant prostate cancer (CRPC) [<CitationRef CitationID="CR4_11">4</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Mechanism of Action</Heading>
            <Para TextBreak="No">Mitoxantrone is an analog of the anthracyclines which intercalates DNA. Although the exact mechanism of action remains unclear, mitoxantrone intercalates between base pairs of the DNA double helix, resulting in cross links, strand breaks, and inhibition of nucleic acid synthesis. Upon binding to nucleic acids, it inhibits DNA and RNA synthesis by template disordering and steric obstruction [<CitationRef CitationID="CR5_11">5</CitationRef>]. Additionally, replication is decreased by binding to DNA topoisomerase II and seems to inhibit the incorporation of uridine into RNA and thymidine into DNA [<CitationRef CitationID="CR6_11">6</CitationRef>], leading to protein-linked DNA breaks. Again, because of these multiple mechanisms of action, mitoxantrone is active throughout the entire cell cycle.</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Pharmacological Considerations</Heading>
            <Para TextBreak="No">The pharmacokinetic parameters of mitoxantrone are best described by an open three-compartment model [<CitationRef CitationID="CR7_11">7</CitationRef>] as follows.</Para>
            <Section2 ID="Sec4">
              <Heading>Distribution</Heading>
              <Para TextBreak="No">In the concentration range of 26–455 ng/mL, protein binding is 78%. Binding is independent of concentration and is unaffected by phenytoin, doxorubicin, methotrexate, prednisone, heparin, or aspirin [<CitationRef CitationID="CR8_11">8</CitationRef>]. Mitoxantrone distributes into a deep tissue compartment from which it is slowly released, as evidenced by prolonged plasma terminal phase half-life, extremely large volume of distribution, and the relatively large amount (&gt;15% of administered dose) retained in tissue at ∼35 days postdose [<CitationRef CitationID="CR9_11">9</CitationRef>]. The distribution half-life is 1.1–3.1 h, mean α half-life is 6–12 min, and mean β half-life is 1.1–3.1 h [<CitationRef CitationID="CR8_11">8</CitationRef>–<CitationRef CitationID="CR10_11">10</CitationRef>]. The volume of distribution is greater than 1,000 L/m<Superscript>2</Superscript> and has been reported at 1,382–3,792 L, specifically. This has also been reported as 14 L/kg in patients with normal hepatic function. In patients with hepatic disease, this drops to 11 L/kg [<CitationRef CitationID="CR7_11">7</CitationRef>, <CitationRef CitationID="CR8_11">8</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec5">
              <Heading>Metabolism</Heading>
              <Para TextBreak="No">Mitoxantrone undergoes extensive metabolism, mostly in the liver, to two inactive metabolites, a monocarboxylic acid derivative and a dicarboxylic acid derivative. Again, neither of these metabolites are cytocidal. Abnormal liver function leads to decreased rates of total body mitoxantrone clearance [<CitationRef CitationID="CR11_11">11</CitationRef>], suggesting a possible need for dose reduction in patients with severe hepatic impairment. Although reported AUCs in patients with severe hepatic impairment or third spacing are more than threefolds of that of patients with normal hepatic function, no definitive dose reductions have been established.</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Excretion</Heading>
              <Para TextBreak="No">Renal clearance of mitoxantrone has been reported in the range of 26.2–70 mL/min [<CitationRef CitationID="CR7_11">7</CitationRef>–<CitationRef CitationID="CR9_11">9</CitationRef>]. Within five days of administration, 11% or less of the drug is recovered in the urine. Of this, 65% is excreted unchanged. Because of this minimal renal excretion, it is unlikely that dose adjustments would be needed in patients with renal impairment. 18.3% of the drug is excreted via the biliary tract, and most importantly, 25% is recovered in the feces. The terminal elimination half-life has been reported from 23 to 215 h and is significantly increased with hepatic impairment or third spacing.</Para>
              <Para TextBreak="No">Mitoxantrone is extensively bound to tissues; therefore, neither the therapeutic nor the toxic effects would be lessened by hemodialysis or peritoneal dialysis [<CitationRef CitationID="CR8_11">8</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec7">
              <Heading>Drug Interactions</Heading>
              <Para TextBreak="No">Early studies with mitoxantrone demonstrated a low potential for drug–drug interactions, other than a significantly increased risk of infection when administered concomitantly with live vaccines. Administration of live vaccines to patients who are immunocompromised by chemotherapeutic agents has resulted in severe and sometimes fatal infections [<CitationRef CitationID="CR12_11">12</CitationRef>, <CitationRef CitationID="CR13_11">13</CitationRef>]. Live virus and bacterial vaccines should not be administered to patients undergoing immunosuppressive chemotherapy. At least a 3 month washout period should elapse between discontinuation of chemotherapy and vaccination with a live vaccine (Table <InternalRef RefID="Tab1">11.1</InternalRef>) [<CitationRef CitationID="CR13_11">13</CitationRef>]. Patients with hormone-dependent tumors should be instructed to avoid black cohosh and dong quai [<CitationRef CitationID="CR14_11">14</CitationRef>].<Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 11.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Live vaccines</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="1">
                    <colspec colname="c1" colnum="1"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Bacillus of Calmette and Guerin (BCG) vaccine</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Measles virus vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Mumps virus vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Poliovirus vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Rotavirus vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Rubella virus vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Smallpox vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Typhoid vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Varicella virus vaccine</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Yellow fever vaccine</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>Safety and Precautions</Heading>
            <Para TextBreak="No">In early single-agent studies, the most commonly reported adverse reactions for mitoxantrone were nausea and vomiting or stomatitis. Patients infrequently encountered diarrhea, abdominal pain and constipation, mild irritation at the site of infusion, shortness of breath, infection, lethargy, weakness, and fatigue. A small number of patients reported altered taste or nail changes. Overall, the adverse reaction profile for mitoxantrone was found to be superior to that of doxorubicin [<CitationRef CitationID="CR15_11">15</CitationRef>].</Para>
            <Para TextBreak="No">Currently, there are five black box warnings described in the US package insert [<CitationRef CitationID="CR6_11">6</CitationRef>]: (1) Mitoxantrone should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents. Mitoxantrone is considered a high-alert medication by the Institute for Safe Medication Practices (ISMP), and may cause significant harm if medication errors occur [<CitationRef CitationID="CR16_11">16</CitationRef>]. Dosage should be reduced in patients with impaired hepatobiliary function. Safety and efficacy in children has not been established yet. (2) Mitoxantrone should be given slowly into a freely flowing intravenous infusion. It must never be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. Mitoxantrone is not for intrathecal use. Severe injury with permanent sequelae can result from intrathecal administration. (3) Except for the treatment of acute nonlymphocytic leukemia, mitoxantrone generally should not be administered to patients with baseline neutrophil counts less than 1,500 cells/mm³. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving mitoxantrone. (4) Use of mitoxantrone has been associated with cardiotoxicity. Cardiotoxicity can occur at any time during mitoxantrone therapy, and the risk increases with cumulative dose. Congestive heart failure (CHF), potentially fatal, may occur either during therapy with mitoxantrone or months to years after termination of therapy. All patients should be carefully assessed for cardiac signs and symptoms by history and physical examination prior to start of mitoxantrone therapy. Baseline evaluation of left ventricular ejection fraction (LVEF) by echocardiogram or multigated radionuclide angiography (MUGA) should be performed prior to initiation of therapy. Patients with a baseline LVEF less than 50% generally should not be treated with mitoxantrone. LVEF should be reevaluated by echocardiogram or MUGA periodically during therapy. Additional doses of mitoxantrone should not be administered to patients who have experienced either a drop in LVEF to below 50% or a clinically significant reduction in LVEF during treatment with mitoxantrone. Patients generally should not receive a cumulative dose greater than 140 mg/m². In cancer patients, the risk of symptomatic congestive heart failure (CHF) was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m². Presence or history of cardiovascular disease, prior or concomitant radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or concomitant use of other cardiotoxic drugs may increase the risk of cardiac toxicity; however, cardiac toxicity with mitoxantrone may occur whether or not cardiac risk factors are present. (5) Secondary acute myelogenous leukemia (AML) has been reported in patients treated with mitoxantrone. Postmarketing cases of secondary AML have also been reported. In 1,774 patients with breast cancer who received mitoxantrone concomitantly with other cytotoxic agents and radiotherapy, the cumulative risk of developing treatment-related AML, was estimated as 1.1% and 1.6% at 5 and 10 years, respectively. Secondary acute myelogenous leukemia (AML) has also been reported in cancer patients treated with anthracyclines, and mitoxantrone, an anthracenedione, is a related drug. The occurrence of refractory secondary leukemia is more common when anthracyclines are given in combination with DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. Similar risk factors should be anticipated with mitoxantrone [<CitationRef CitationID="CR17_11">17</CitationRef>]. Most recently, AML incidence was reported at 0.6% for high-risk prostate cancer patients undergoing adjuvant chemotherapy with mitoxantrone. This is similar to the rates of AML reported in breast cancer patients treated with mitoxantrone [<CitationRef CitationID="CR18_11">18</CitationRef>]. Other characteristics of leukemias linked to treatment with topoisomerase II inhibitors are a latency period of approximately 2 years and balanced chromosomal aberrations [<CitationRef CitationID="CR19_11">19</CitationRef>]. Many of these leukemias have translocations involving the 11q23 band, though inv [<CitationRef CitationID="CR17_11">17</CitationRef>] and t [<CitationRef CitationID="CR15_11">15</CitationRef>–<CitationRef CitationID="CR17_11">17</CitationRef>] abnormalities are also seen [<CitationRef CitationID="CR20_11">20</CitationRef>].</Para>
            <Para TextBreak="No">In addition to these warnings, adverse reactions that have been reported to date in greater than 10% of patients are as follows: central nervous system (CNS): pain, fatigue, weakness, fever, and headache; dermatologic: alopecia and nail bed changes; endocrine/metabolic: amenorrhea, menstrual disorder, and hyperglycemia; gastrointestinal (GI): abdominal pain, anorexia, nausea, constipation, diarrhea, GI bleeding, mucositis, stomatitis, dyspepsia, vomiting, and weight gain/loss; genitourinary (GU): abnormal urine and urinary tract infection; hematologic: neutropenia, leukopenia, lymphopenia, anemia, thrombocytopenia, and petechiae/bruising; hepatic: increased liver function tests (LFTs); renal: increased creatinine/BUN and hematuria; respiratory: cough, dyspnea, and upper respiratory tract infections; and miscellaneous: fungal infections and sepsis. An additional 1–10% of patients experienced the following: central nervous system (CNS): chills, anxiety, depression, and seizures; dermatologic: cellulitis; endocrine/metabolic: hypocalcemia, hypokalemia, hyponatremia, and mennorhagia; gastrointestinal (GI): aphthosis; genitourinary (GU): impotence and sterility; hematologic: hemorrhage; hepatic: jaundice; neuromuscular: back pain, myalgia, and arthralgia; ocular: conjunctivitis and blurred vision; renal: renal failure and proteinuria; respiratory: rhinitis, sinusitis, and pneumonia; and miscellaneous: diaphoresis [<CitationRef CitationID="CR14_11">14</CitationRef>].</Para>
            <Para TextBreak="No">Incidence of these adverse reactions varies based on treatment and dose administered. Although it is not a clinically significant toxicity, patients should be counseled that mitoxantrone may cause urine, tears, saliva, sweat, and the whites of the eyes to have a blue-green tinge for 24 h postinfusion [<CitationRef CitationID="CR17_11">17</CitationRef>].</Para>
            <Para TextBreak="No">Mitoxantrone is classified as a Pregnancy Category D. When administered during pregnancy, it can cause fetal harm in humans. Animal studies have shown delayed fetal development, fetal external anomalies, and neonatal abnormalities [<CitationRef CitationID="CR16_11">16</CitationRef>]. The risk to the fetus from semen of the male is unknown.</Para>
            <Para TextBreak="No">Symptoms of overdose include leukopenia, tachycardia, and marrow hypoplasia. There is no known antidote available [<CitationRef CitationID="CR14_11">14</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec9">
            <Heading>Dosing and Administration</Heading>
            <Para TextBreak="No">The dose of mitoxantrone for CRPC is 12–14 mg/m<Superscript>2</Superscript> administered intravenously (IV) every 3 weeks as a 30-min intravenous infusion, in combination with a corticosteroid [<CitationRef CitationID="CR21_11">21</CitationRef>, <CitationRef CitationID="CR22_11">22</CitationRef>]. Mitoxantrone should not be administered by intra-arterial, subcutaneous, intramuscular, or intrathecal routes. Diluted solutions of mitoxantrone should be infused into free-flowing normal saline (NS) or 5% dextrose in water solution (D5W). Because mitoxantrone is a known vesicant, care should be taken to avoid extravasation or any contact with the skin, eyes, or mucosa. Infusion should be stopped immediately if extravasation occurs, and the site should be monitored for signs of necrosis or phlebitis that may require medical attention [<CitationRef CitationID="CR8_11">8</CitationRef>–<CitationRef CitationID="CR15_11">15</CitationRef>, <CitationRef CitationID="CR17_11">17</CitationRef>]. Therapy should not be initiated in patients with baseline neutrophil counts less than 1,500 cells/mm<Superscript>3</Superscript> [<CitationRef CitationID="CR14_11">14</CitationRef>].</Para>
            <Section2 ID="Sec10">
              <Heading>Cumulative Dose Limits</Heading>
              <Para TextBreak="No">Similar to doxorubicin, mitoxantrone has been associated with cardiomyopathy when cumulative doses reach 80–120 mg/m<Superscript>2</Superscript> or if administered for periods exceeding 9–12 months. Caution should be exercised when approaching either of these limits [<CitationRef CitationID="CR23_11">23</CitationRef>, <CitationRef CitationID="CR24_11">24</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec11">
              <Heading>Dosage in Renal Impairment</Heading>
              <Para TextBreak="No">As only small amounts (∼7%) are excreted unchanged into the urine, dosing adjustments are not necessary in renal impairment [<CitationRef CitationID="CR25_11">25</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec12">
              <Heading>Dosage in Hepatic Impairment</Heading>
              <Para TextBreak="No">Mitoxantrone clearance is significantly reduced in patients with severe hepatic impairment or third spacing, and terminal half-life is doubled. Though a reduction in dosage is advised [<CitationRef CitationID="CR25_11">25</CitationRef>], no specific dose adjustments are suggested.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec13">
            <Heading>Efficacy</Heading>
            <Para TextBreak="No">Mitoxantrone was approved in 1996 for use in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to CRPC [<CitationRef CitationID="CR4_11">4</CitationRef>]. In multiple large randomized studies, mitoxantrone plus prednisone was shown to reduce pain and increase quality of life for patients with CRPC, though it does not extend survival [<CitationRef CitationID="CR26_11">26</CitationRef>, <CitationRef CitationID="CR27_11">27</CitationRef>]. Subsequent to the approval of docetaxel as treatment for CRPC, mitoxantrone has primarily been used as a second-line therapy.</Para>
          </Section1>
          <Section1 ID="Sec14">
            <Heading>Place in Therapy</Heading>
            <Para TextBreak="No">In the natural history of prostate cancer, CRPC occurs during the final 2–3 years of life [<CitationRef CitationID="CR28_11">28</CitationRef>]. Initial treatment of metastatic disease by orchiectomy, which is the patient-preferred treatment in Europe; or by therapy with drugs that decrease androgen stimulation, the patient-preferred treatment in the United States [<CitationRef CitationID="CR29_11">29</CitationRef>]; can relieve symptoms related to pelvic node and bone metastases in approximately 75% of patients, but all patients eventually progress to castration-resistant disease. Although many of these patients are elderly with significant comorbidities and increased potential for toxicity, cytotoxic chemotherapy has been shown to significantly prolong survival in men with CRPC [<CitationRef CitationID="CR21_11">21</CitationRef>, <CitationRef CitationID="CR22_11">22</CitationRef>, <CitationRef CitationID="CR26_11">26</CitationRef>, <CitationRef CitationID="CR30_11">30</CitationRef>].</Para>
            <Para TextBreak="No">Prostate cancer was largely considered resistant to chemotherapy until the mid-1990s when mitoxantrone plus prednisone (MP) was shown to provide palliation for patients with CRPC [<CitationRef CitationID="CR21_11">21</CitationRef>]. To date, three drugs – docetaxel, estramustine, and mitoxantrone – have been approved by the FDA for first-line treatment of CRPC (See Table <InternalRef RefID="Tab2">11.2</InternalRef>). Mitoxantrone is indicated in combination with steroids as initial chemotherapy for palliation of pain related to advanced CRPC. Mitoxantrone and prednisone have nearly twice the response of prednisone alone with significantly more durable responses [<CitationRef CitationID="CR31_11">31</CitationRef>]. As a single agent, mitoxantrone has palliative activity and is well tolerated in elderly patients [<CitationRef CitationID="CR8_11">8</CitationRef>, <CitationRef CitationID="CR32_11">32</CitationRef>].<Table Float="Yes" ID="Tab2">
                <Caption Language="En">
                  <CaptionNumber>Table 11.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Trials of mitoxantrone in castration resistant prostate cancer (CRPC) [<CitationRef CitationID="CR26_11">26</CitationRef>, <CitationRef CitationID="CR27_11">27</CitationRef>, <CitationRef CitationID="CR32_11">32</CitationRef>–<CitationRef CitationID="CR35_11">35</CitationRef>]</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Publication year</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Author</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Number of patients</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Setting</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Study results</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>2004</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Tannock</SimplePara>
                        <SimplePara>(TAX327)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>1,006</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Mitoxantrone/prednisone (MP) vs. weekly (D1P) or Q3 weekly docetaxel (D3P) with prednisone as first-line chemotherapy in CRPC</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Median overall survival was 19.2 months in the D3P arm (95% CI, 17.5–21.3), 17.8 months in the D1P arm (95% CI, 16.2–19.2) and 16.3 months in the MP arm (95% CI, 14.3–17.9) respectively.</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>2004</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Petrylak</SimplePara>
                        <SimplePara>(SWOG 99–16)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>770</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Docetaxel/estramustine vs. mitoxantrone/prednisone as first-line chemotherapy in CRPC</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Median overall survival was prolonged in the docetaxel/estramustine group compared to mitoxantrone/prednisone – 17.5 months vs. 15.6 months (<Emphasis Type="Italic">P</Emphasis> = 0.02)</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>2006</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Michels</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>68</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Mitoxantrone vs. docetaxel in either sequence for CRPC</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Front-line docetaxel prolonged median overall survival compared to front-line Mitoxantrone – 22 months (95% CI, 17.2–26.8) vs. 15 months (95% CI, 10.4–19.6)</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>2006</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Hart</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>78</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Irofulven/prednisone (IP) vs. Irofulven/capecitabine (IC) vs. mitoxantrone/prednisone (MP) as second-line chemotherapy for CRPC</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>TTP 2.1 months (IP and IC) vs. 1.1 months (MP)</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>2007</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Rosenberg</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>82</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Ixabepilone vs. mitoxantrone/prednisone in CRPC progressing through first-line chemotherapy</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Median overall survival 10.4 months for ixabepilone arm vs. 9.8 months for mitoxantrone arm</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
            <Para TextBreak="No">In 2004, a large trial TAX327,comparing mitoxantrone to docetaxel in castration-resistant prostate cancer, randomized patients to receive docetaxel 75 mg/m<Superscript>2</Superscript> administered every 3 weeks, docetaxel 30 mg/m<Superscript>2</Superscript> administered weekly for 5 of 6 weeks, or mitoxantrone 12 mg/m<Superscript>2</Superscript> every 3 weeks, each with prednisone 5 mg orally twice daily. On the basis of this study’s findings, the FDA approved docetaxel in combination with prednisone for treatment of CRPC. Updated survival analysis of the study confirmed that survival is significantly increased in patients receiving docetaxel plus prednisone every 3 weeks compared to those receiving mitoxantrone plus prednisone. The difference in median overall survival time is now reported at 2.9 months (<Emphasis Type="Italic">P</Emphasis> = 0.004, HR=0.79).</Para>
            <Para TextBreak="No">Treatment with weekly docetaxel, however, did not lead to an increase in overall survival, and patients on this arm of the trial were more likely to experience deterioration in quality of life due to disease progression or increased toxicities. In general, patients with visceral disease, pain, poorer performance status, and higher baseline PSA had shorter survival times.</Para>
            <Para TextBreak="No">Treatment with docetaxel and estramustine has also demonstrated a survival advantage over the combination of mitoxantrone and prednisone. In addition to TAX327, a second pivotal trial in 2004, SWOG 99–16 randomly assigned patients to either 280 mg estramustine orally three times daily 1 h before or 2 h after meals on days 1–5 plus docetaxel 60 mg/m<Superscript>2</Superscript> on day 2 or mitoxantrone 12 mg/m<Superscript>2</Superscript> on day 1 plus prednisone 5 mg twice daily. After intent-to-treat analysis, median survival was 17.5 months among the patients assigned to estramustine and docetaxel and 15.6 months among the patients assigned to mitoxantrone and prednisone (<Emphasis Type="Italic">P</Emphasis> = 0.02); the corresponding hazard ratio for death was 0.8 [<CitationRef CitationID="CR27_11">27</CitationRef>]. Again the trade-off was an increased incidence of adverse events in the estramustine and docetaxel arm, specifically cardiovascular and gastrointestinal events, though these were not associated with either an increased rate of treatment discontinuation or treatment-related deaths [<CitationRef CitationID="CR27_11">27</CitationRef>, <CitationRef CitationID="CR28_11">28</CitationRef>].</Para>
            <Para TextBreak="No">Patients who progress after first-line chemotherapy have limited treatment options, none of which are FDA-approved. In fact, it has been reported that less than half of men with CRPC will receive a second-line therapy [<CitationRef CitationID="CR33_11">33</CitationRef>]. In 2006, a study of 68 men with CRPC evaluated the sequencing of first- and second-line treatment with docetaxel and mitoxantrone. This study favored initial treatment with docetaxel, and although second-line docetaxel lead to a higher PSA response than second-line mitoxantrone (38% vs. 12%, <Emphasis Type="Italic">P</Emphasis> = 0.012), both docetaxel and mitoxantrone have limited tolerability in the second-line setting, with significant rates of treatment-related adverse events, dose reductions, dose delays, or discontinuation of therapy (64% and 46% of patients, respectively) [<CitationRef CitationID="CR34_11">34</CitationRef>]. For patients with taxane-refractory CRPC, defined as progression during or within 60 days of cessation of taxane therapy, mitoxantrone with prednisone 5 mg twice daily has been shown to have modest activity as a second-line agent. Elevated lactate dehydrogenase and the presence of visceral metastases are both poor prognostic indicators in the second-line setting. Patients experiencing a PSA response to prior therapy were 7–8 times more likely to respond to second-line treatment, and patients who have had no response to taxanes are unlikely to have a response to mitoxantrone [<CitationRef CitationID="CR32_11">32</CitationRef>]. For this population of men who are candidates for second-line chemotherapy, investigational agents should be considered.</Para>
          </Section1>
          <Section1 ID="Sec15" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">Systemic chemotherapy should be reserved only for patients with metastatic CRPC unless under study in clinical trials. Mitoxantrone plus prednisone was shown to reduce pain and increase quality of life for patients with CRPC, though it does not extend survival. Subsequent to the approval of docetaxel as treatment for CRPC, mitoxantrone has primarily been used as a second-line therapy. In addition to the discovery of newer agents to be used both in first- and second-line chemotherapy, important decisions regarding the direction of future clinical trials in prostate cancer remain, specifically the endpoints that are most beneficial to the patient and/or valid to the scientific community. Although survival remains the conventional FDA-preferred endpoint, with surrogate markers of progression-free survival and the related time to progression, future clinical trials of patients with CRPC must also take into consideration the clinical experience of patients (pain and other quality of life measures) and the utility of parameters such as PSA measurements and circulating tumor cells to predict survival. Treatment decisions must be individualized based on tumor characteristics, efficacy data, toxicity profile, convenience of scheduling, and impact on quality of life, as well as survival statistics.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_11.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_11">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>White</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FE</Initials>
                  <FamilyName>Durr</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">Development of mitoxantrone</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>85</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>2410393</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00174154</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2MXltlChs74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>White RJ, Durr FE. Development of mitoxantrone. Invest New Drugs 1985;3:85–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_11">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Paciucci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Dutcher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Cuttner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Strauman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Wiernik</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Holland</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia</ArticleTitle>
                <JournalTitle>Leukemia</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>565</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>3478540</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1c%2FjslGgtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, Holland JF. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987;1:565–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_11">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Spadea</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Petti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Fazi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia</ArticleTitle>
                <JournalTitle>Leukemia</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>549</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>8464233</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s3hvVaksA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Spadea A, Petti MC, Fazi P et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 1993;7:549–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_11">
              <CitationNumber>4.</CitationNumber>
              <BibUnstructured>U.S. Food and Drug Administration Center for Drug Evaluation and Research Approval Summary for Mitoxantrone. (Accessed May 6, 2008, at <ExternalRef>
                  <RefSource>www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=91</RefSource>
                  <RefTarget Address="http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=91" TargetType="URL"/>
                </ExternalRef>).</BibUnstructured>
            </Citation>
            <Citation ID="CR5_11">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Lown</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CC</Initials>
                  <FamilyName>Hanstock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RD</Initials>
                  <FamilyName>Bradley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Scraba</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy</ArticleTitle>
                <JournalTitle>Mol Pharmacol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>178</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>6708933</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXps1aqtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lown JW, Hanstock CC, Bradley RD, Scraba DG. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Mol Pharmacol 1984;25:178–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_11">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Tewey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Rowe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BD</Initials>
                  <FamilyName>Halligan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LF</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>226</VolumeID>
                <FirstPage>466</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>6093249</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.6093249</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2cXmt1ahs7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_11">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Ehninger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Proksch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Heinzel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Schiller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KH</Initials>
                  <FamilyName>Weible</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Woodward</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">The pharmacokinetics and metabolism of mitoxantrone in man</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>109</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>4019115</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00174157</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2MXltlCgur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 1985;3:109–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_11">
              <CitationNumber>8.</CitationNumber>
              <BibUnstructured>Mitoxantrone. In: Micromedex Healthcare Series: Thomson Health Care; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_11">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Alberts</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YM</Initials>
                  <FamilyName>Peng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT</Initials>
                  <FamilyName>Bowden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WS</Initials>
                  <FamilyName>Dalton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Mackel</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">Pharmacology of mitoxantrone: mode of action and pharmacokinetics</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>101</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>4040505</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2MXltFGlsLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985;3:101–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_11">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Belle</FamilyName>
                  <Particle>Van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Planque</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IE</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1986</Year>
                <ArticleTitle Language="En">Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>18</VolumeID>
                <FirstPage>27</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>3757156</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00253059</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Van Belle SJ, de Planque MM, Smith IE et al. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 1986;18:27–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_11">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Savaraj</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Manuel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Loo</FamilyName>
                </BibAuthorName>
                <Year>1982</Year>
                <ArticleTitle Language="En">Pharmacology of mitoxantrone in cancer patients</ArticleTitle>
                <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>113</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>7094196</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00292881</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL383jsVSjsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Savaraj N, Lu K, Manuel V, Loo TL. Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol 1982;8:113–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_11">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EH</Initials>
                  <FamilyName>Rosenbaum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HR</Initials>
                  <FamilyName>Glatstein</FamilyName>
                </BibAuthorName>
                <Year>1966</Year>
                <ArticleTitle Language="En">Vaccination of a patient receiving immunosuppressive therapy for lymphosarcoma</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>198</VolumeID>
                <FirstPage>737</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="PID">
                  <Handle>5953328</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.1966.03110200093025</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaF2s%2FktVKgtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rosenbaum EH, Cohen RA, Glatstein HR. Vaccination of a patient receiving immunosuppressive therapy for lymphosarcoma. JAMA 1966;198:737–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_11">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Kroger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Atkinson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Marcuse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LK</Initials>
                  <FamilyName>Pickering</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)</ArticleTitle>
                <JournalTitle>MMWR Recomm Rep</JournalTitle>
                <VolumeID>55</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>48</LastPage>
                <Occurrence Type="PID">
                  <Handle>17136024</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1–48.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_11">
              <CitationNumber>14.</CitationNumber>
              <BibBook>
                <BibEditorName>
                  <Initials>CF</Initials>
                  <FamilyName>Lacy</FamilyName>
                </BibEditorName>
                <Eds/>
                <Year>2008</Year>
                <BookTitle>Drug Information Handbook</BookTitle>
                <EditionNumber>16</EditionNumber>
                <PublisherName>Lexi-Comp</PublisherName>
                <PublisherLocation>Hudson, OH</PublisherLocation>
              </BibBook>
              <BibUnstructured>Lacy CF ed. Drug Information Handbook. 16 ed. Hudson, OH: Lexi-Comp. 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_11">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LE</Initials>
                  <FamilyName>Posner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Dukart</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Goldberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Bernstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Cartwright</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">Mitoxantrone: an overview of safety and toxicity</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>123</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="PID">
                  <Handle>3894276</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/BF00174159</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2MXlslWmtro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985;3:123–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_11">
              <CitationNumber>16.</CitationNumber>
              <BibUnstructured>ISMP’s List of High Alert Medications. 2008. (Accessed June 13, 2008, at <ExternalRef>
                  <RefSource>http://www.ismp.org/Tools/highalertmedications.pdf</RefSource>
                  <RefTarget Address="http://www.ismp.org/Tools/highalertmedications.pdf" TargetType="URL"/>
                </ExternalRef>.)</BibUnstructured>
            </Citation>
            <Citation ID="CR17_11">
              <CitationNumber>17.</CitationNumber>
              <BibUnstructured>Novantrone (mitoxantrone) Package Insert. In. Melville, NY: OSI Oncology; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_11">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>TW</Initials>
                  <FamilyName>Flaig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>1532</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18349405</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.13.4197</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXkslKqsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Flaig TW, Tangen CM, Hussain MH et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008;26:1532–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_11">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Pedersen-Bjergaard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Rowley</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation</ArticleTitle>
                <JournalTitle>Blood</JournalTitle>
                <VolumeID>83</VolumeID>
                <FirstPage>2780</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8180374</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXlsFChsbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_11">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Pedersen-Bjergaard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Andersen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Johansson</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>1897</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>9586907</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXjtFOqtrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998;16:1897–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_11">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Osoba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Stockler</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>1756</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>8656243</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XjslOrsr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_11">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Conaway</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>2506</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>10561316</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXltlyltL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_11">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MN</Initials>
                  <FamilyName>Maisey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Knight</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RD</Initials>
                  <FamilyName>Rubens</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Mitoxantrone in advanced breast cancer–a phase II study with special attention to cardiotoxicity</ArticleTitle>
                <JournalTitle>Eur J Cancer Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>771</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>6540179</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0277-5379(84)90215-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3mtFKgtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Coleman RE, Maisey MN, Knight RK, Rubens RD. Mitoxantrone in advanced breast cancer – a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 1984;20:771–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_11">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Stuart-Harris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Pearson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IE</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EG</Initials>
                  <FamilyName>Olsen</FamilyName>
                </BibAuthorName>
                <Year>1984</Year>
                <ArticleTitle Language="En">Cardiotoxicity associated with mitoxantrone</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>219</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>6146768</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(84)90498-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c3mvFCgug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stuart-Harris R, Pearson M, Smith IE, Olsen EG. Cardiotoxicity associated with mitoxantrone. Lancet 1984;2:219–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_11">
              <CitationNumber>25.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Savaraj</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Valdivieso</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1982</Year>
                <ArticleTitle Language="En">Clinical kinetics of 1, 4-dihydroxy-5, 8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>31</VolumeID>
                <FirstPage>312</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7060314</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/clpt.1982.39</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL387jslKhsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Savaraj N, Lu K, Valdivieso M et al. Clinical kinetics of 1,4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino-9, 10-anthracenedione. Clin Pharmacol Ther 1982;31:312–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_11">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Berry</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1502</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470213</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa040720</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_11">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>1513</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>15470214</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa041318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXot1Kmu7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_11">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hussain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Petrylak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Fisher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916</ArticleTitle>
                <JournalTitle>Semin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>55</FirstPage>
                <LastPage>60</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604271</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivVagsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol 1999;26:55–60.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_11">
              <CitationNumber>29.</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kolesar</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ChapterTitle Language="En">Oncology pharmacy preparatory review course – prostate cancer</ChapterTitle>
                <BibEditorName>
                  <Initials>ACoC</Initials>
                  <FamilyName>Pharmacy</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Oncology Pharmacy Preparatory Review Course</BookTitle>
                <PublisherName>American College of Clinical Pharmacy</PublisherName>
                <PublisherLocation>Fort Lauderdale, FL</PublisherLocation>
                <FirstPage>203</FirstPage>
                <LastPage>22</LastPage>
              </BibChapter>
              <BibUnstructured>Kolesar J. Oncology pharmacy preparatory review course – prostate cancer In: Pharmacy ACoC, editor. Oncology Pharmacy Preparatory Review Course; 2006; Fort Lauderdale, Florida: American College of Clinical Pharmacy; 2006. p. 203–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_11">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Berthold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Pond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Soban</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Wit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eisenberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>242</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>18182665</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.12.4008</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXitVWitLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_11">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Osoba</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Tannock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Ernst</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AJ</Initials>
                  <FamilyName>Neville</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>1654</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>10561201</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXktV2qtL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_11">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Rosenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VK</Initials>
                  <FamilyName>Weinberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Kelly</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>110</VolumeID>
                <FirstPage>556</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>17577218</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.22811</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXpt1yqu7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_11">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EG</Initials>
                  <FamilyName>Garmey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Halabi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Vogelzang</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Second-line chemotherapy for advanced hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Clin Adv Hematol Oncol</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>118</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="PID">
                  <Handle>18347563</Handle>
                </Occurrence>
                <BibComments>27–32</BibComments>
              </BibArticle>
              <BibUnstructured>Garmey EG, Sartor O, Halabi S, Vogelzang NJ. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008;6:118–22, 27–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_11">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Michels</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Montemurro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Murray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kollmannsberger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nguyen Chi</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>106</VolumeID>
                <FirstPage>1041</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>16456811</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.21695</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xis1agtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 2006;106:1041–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_11">
              <CitationNumber>35.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Hart</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Ciuleanu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hainsworth</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Randomized Phase 11 Trial of irofulven (IROF)/prednisone(P), IROF/Capecitabine(C)/P or mitoxantrone (M)/P in docetaxel pre-treated hormone refractory prostate cancer (HRPC) patients</ArticleTitle>
                <JournalTitle>J clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>14513</FirstPage>
              </BibArticle>
              <BibUnstructured>Hart L, Ciuleanu T, Hainsworth J et al. Randomized Phase 11 Trial of irofulven (IROF)/prednisone(P), IROF/Capecitabine(C)/P or mitoxantrone (M)/P in docetaxel pre-treated hormone refractory prostate cancer (HRPC) patients. J clin Oncol 2006;24(18S pt):Abstract 14513.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
